The Mumbai-based company has installed a production line in Guwahati to enhance the manufacturing capacity of sterile products
India's Sun Pharma has celebrated the opening of a new production line at its site in Guwahati, a city near the Brahmaputra River in the northeast Indian state of Assam.
The company made an investment of Rs. 120 crores (US$16.3m) to set up the production line in the parenteral block. The facility has two main blocks, namely oral solid dosage and parenteral.
The production line, inaugurated on Saturday 13 October, will enhance the company’s capacity to manufacture liquid vials, lyophilized vials, liquid ampoule and eye drops.
The facility is capable of manufacturing tablets, capsules, sex hormones, injectable and eye care products and is spread over an area of 14 acres (5.66 ha). Sun Pharma said it has invested Rs. 700 crores (US$95.2m) up to date in setting up the Guwahati facility. The operations at the site commenced in 2016.
Speaking at the opening ceremony, Dilip Shanghvi, Managing Director, Sun Pharma, said, “Sun Pharma is committed to the Government’s ‘Make in India’ initiative. Our investment in Assam is an example of the Hon’ble Chief Minister, Shri Sonowalji’s vision of boosting industrial activities and generating employment opportunities in the state of Assam. In the next few years, the Guwahati plant is expected to become one of the largest facilities in our network to manufacture sterile products.”
The state-of-the-art facility is designed to meet global cGMP requirements and standards. It is equipped with automated machines for granulation, tablet compression, capsule filling, eye drops, vial and ampule filling, coating and packing.
Material management, operations and laboratory systems are controlled through computerised systems to bring in efficiency and enhance productivity.
The facility operates under ‘Zero Discharge’ norms. The treated effluent is 100% recycled within site for gardening, cooling tower and toilet flushing system.
Sun Pharma’s global presence is supported by 42 manufacturing facilities spread across India, the Americas, Asia, Africa, Australia and Europe. The company has 23 manufacturing facilities in India.
The company said it fosters excellence through innovation supported by R&D capabilities comprising about 2,000 scientists and R&D investments of approximately 8% of annual revenues.